×
ADVERTISEMENT

APRIL 7, 2025

FDA Approves Qfitlia for Hemophilia A or B


Originally published by our sister publication Specialty Pharmacy Continuum

By SPC Staff

The FDA approved fitusiran (Qfitlia, Sanofi) for adults and children 12 years of age and older with hemophilia A or B, with or without factor VIII or IX inhibitors. The medication is indicated for routine use to prevent or reduce the frequency of bleeding episodes and administered subcutaneously starting once every two months. 

Fitusiran reduces the amount of antithrombin to help increase thrombin